ClinicalTrials.gg
CompletedNCT00707980Updated Dec 13, 2013Results posted

Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

A Phase 3 interventional study of Vortioxetine in Major Depressive Disorder, sponsored by Takeda. Completed at 92 sites in 17 countries. Open to participants aged 18 Years to 76 Years. Per ClinicalTrials.gov, last updated 2013-12-13.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
836
Allocation
Not applicable
Ages
18 Years to 76 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.

Enrollment
3rd of 54
836 · median 413
Started
2008
with 5 others
Phase 3
31 of 54
1 open now
Registered
6th of 54
by date
Lead sponsor
17 of 54
Takeda

Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 3rd largest by enrollment, is one of 6 that started in 2008, is one of 31 in phase 3, and was the 6th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vortioxetine

Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 76 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing vortioxetine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The purpose of this study is to determine the long-term efficacy and safety of vortioxetine, once daily (QD), in adults with major depressive disorder.

Read the detailed description

The drug that was tested in this study is called vortioxetine. Vortioxetine is being tested to treat depression in people who have major depressive disorder (MDD). This study looked at MDD relief in people who took vortioxetine.

The study enrolled 836 patients that had completed one of two other vortioxetine studies. Participants received 5 mg of vortioxetine for the first week of treatment. After completing the first week of treatment, the dose could be increased to 10 mg/day or decreased to 2.5 mg/day based on participant's response as judged by the doctor.

All participants were asked to take one encapsulated tablet at the same time each day throughout the study.

This multi-center trial was conducted worldwide. The overall time to participate in this study was up to 56 weeks. Participants made 13 visits to the clinic, and were contacted by telephone 4 weeks after the last dose of study drug for a follow-up assessment.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Major Depressive Disorder
  • Depression
  • Melancholia
  • Mood Disorder
  • Dysthymic Disorder
  • Drug Therapy
04

Who can participate

Ages eligible
18 Years to 76 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has completed the double blind treatment period of either study Lu AA21004_304 (NCT00672620) or LuAA21004_305 (NCT00735709) immediately prior to enrollment in the extension study (ie, the baseline visit is the same visit as the completion visit of the double blind treatment of the preceding protocol).
  • Suffers from a major depressive episode as the primary diagnosis according to , 4th Edition, Text Revision (DSM-IV-TR) criteria (classification code 296.xx) at entry into the prior Lu AA21004_304 or Lu AA21004_305 study.

Exclusion criteria

Exclusion Criteria:

  • In addition to meeting the exclusion criteria for studies Lu AA21004_304 or Lu AA21004_305 at the time of enrollment into those studies respectively, with the exception of the criteria prohibiting previous exposure to Lu AA21004 and drugs, and the criteria prohibiting patients with increased intraocular pressure, or risk of acute narrow-angle glaucoma, the following exclusion criteria apply:

    • Has Major Depressive Disorder for whom other psychiatric disorders (mania, bipolar disorder, schizophrenia, or any psychotic disorder) have been diagnosed during the prior study.
    • The participant, in the investigator's opinion, has a significant risk of suicide and/or a score of ≥5 points on item 10 (suicidal thoughts) of the Montgomery Åsberg Depression Rating Scale.
    • The participant, in the opinion of the investigator, is unlikely to comply with the clinical study protocol or is unsuitable for any reason.
    • Has a moderate or severe ongoing adverse event related to study medication from the prior study.
    • Has used/uses disallowed concomitant medication.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
836 participants (actual)

Study arms

  • Experimental
    Vortioxetine

    Vortioxetine 2.5 mg, 5 mg or 10 mg, encapsulated tablets, orally, once daily for up to 52 weeks. For the first week of treatment all participants received 5 mg/day vortioxetine, thereafter, the dose could be increased to 10 mg/day or decreased to 2.5 mg/day, based on participant's response and tolerability as judged by the investigator.

    Drug: Vortioxetine

Interventions

  • Encapsulated vortioxetine immediate-release tablets

    Also known as: Lu AA21004, Brintellix®

06

What researchers measure

Primary outcomes

  1. Physical Examination Findings

    Physical examination consisted of the following body systems: (1) appearance; (2) extremities; (3) skin; (4) head and neck; (5) eyes, ears, nose, and throat; (6) lungs and chest; (7) heart and cardiovascular system; (8) abdomen; and (9) musculoskeletal system. An assessment of the nervous system was conducted; any findings were captured under the appropriate body area. Each system was assessed as normal or abnormal.

    Time frame: Baseline and Week 52

  2. Number of Participants With Potentially Clinically Significant Laboratory Evaluation Findings

    Participants with at least one post-baseline potentially clinically significant (as defined in the table below) serum chemistry, hematology or urinalysis result. ULN = upper limit of normal; LLN = Lower limit of normal.

    Time frame: Weeks 4, 8, 12, 20, 28, 36, 44 and 52

  3. Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Findings

    A standard 12-lead ECG was performed at the designated study visits. The central reader reviewed and recorded the intervals (PR, QRS, RR, QT, and corrected QT interval \[QTc\]), and interpreted the ECG using 1 of the following categories: within normal limits or abnormal. The number of participants with at least one post-baseline potentially clinically significant ECG finding is reported. bpm = beats per minute; QTcB = QT interval corrected using Bazett's formula; QTcF = QT interval corrected using Fridericia's formula.

    Time frame: Weeks 4, 12, 24, 36 and 52

  4. Number of Participants With Adverse Events (AEs)

    The intensity (severity) of each AE was defined as: * Mild: caused minimal discomfort and did not interfere in a significant manner with normal activities. * Moderate: sufficiently uncomfortable to produce some impairment of normal activities. * Severe: incapacitating, preventing the patient from participating in normal activities. The causal relationship between an AE and study drug was assessed by the investigator as Probable, Possible or Not Related; Related=AEs with causality of Possibly or Probably. A serious AE (SAE) was defined as any untoward medical occurrence that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, led to a congenital anomaly/birth defect, or was an important medical event that either jeopardized the patient, required intervention to prevent any of the SAEs defined above, a suicide attempt or an abortion.

    Time frame: From the first dose of open-label study drug until 4 weeks after the last dose (up to 56 weeks)

  5. Number of Participants With Potentially Clinically Significant Vital Sign Findings

    Participants with at least one potentially clinically significant post-baseline vital sign finding. The definition of clinically significant is included in the table below for each parameter. SSBP = supine systolic blood pressure; SDBP = supine diastolic blood pressure.

    Time frame: Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 36, 44 and 52

Secondary outcomes

  1. Change From Baseline in Hamilton Depression Scale-24 Item (HAM-D24) Total Score

    The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74 where a higher score indicates a greater depressive state. Final Visit includes data from Week 52 or earlier for participants who didn't complete the 52 weeks.

    Time frame: Baseline and Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 36, 44 and 52.

  2. Change From Baseline in the Montgomery Åsberg Depression Rating Scale (MADRS) Total Score

    The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). Decrease in the total score or on individual items indicates improvement. Final Visit includes data from Week 52 or earlier for participants who didn't complete the 52 weeks.

    Time frame: Baseline and Weeks 4, 24 and 52

  3. Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score

    The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56, where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. Final Visit includes data from Week 52 or earlier for participants who didn't complete the 52 weeks.

    Time frame: Baseline and Weeks 4, 24 and 52

  4. Change From Baseline in the Clinical Global Impression of Severity of Illness Scale

    The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. Final Visit includes data from Week 52 or earlier for participants who didn't complete the 52 weeks.

    Time frame: Baseline and Weeks 4, 24 and 52

  5. Change From Baseline to the Final Visit in 36-item Short-form Health Survey (SF-36)

    The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The 8 health concepts are: 1. Limitation in physical activities because of health problems. 2. Limitations in usual role activities because of physical health problems. 3. Bodily pain. 4. Limitations in social activities because of physical or emotional problems. 5. General mental health (psychological distress and well-being). 6. Limitations in usual role activities because of emotional problems. 7. Vitality (energy and fatigue). 8. General health perception. Each scale ranges from 0 (best) - 100 (worst).

    Time frame: Baseline and Week 52

  6. Change From Baseline to the Final Visit in the Sheehan Disability Scale

    The Sheehan Disability Scale (SDS) assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment.

    Time frame: Baseline and Week 52

  7. Health Care Resource Utilization Assessed by the Health Economic Assessment Questionnaire

    Healthcare resource utilization was assessed by the Health Economic Assessment (HEA) questionnaire, which monitors participants absenteeism from work, as well as resource use such as visits to a general practitioner, outpatient and inpatient services, hospitalization, medications, and other relevant services over the past 8 weeks.

    Time frame: Baseline and Week 52

07

Results

Posted Dec 13, 2013

Participant flow

Participants took part in the study at 88 investigative sites in Australia, Croatia, France, Germany, Korea, Latvia, Lithuania, Malaysia, The Netherlands, Poland, Russia, Taiwan, Ukraine, and the United States from 17 June 2008 to 23 August 2010.

Participant flow — Overall Study
MilestoneVortioxetine
Started836
Received treatment834
Completed526
Not completed310
Withdrew: Adverse event49
Withdrew: Lack of efficacy35
Withdrew: Non-compliance with study drug28
Withdrew: Protocol deviations19
Withdrew: Withdrawal of consent81
Withdrew: Lost to follow-up59
Withdrew: Other39

Outcome measures

PrimaryPhysical Examination Findings

Physical examination consisted of the following body systems: (1) appearance; (2) extremities; (3) skin; (4) head and neck; (5) eyes, ears, nose, and throat; (6) lungs and chest; (7) heart and cardiovascular system; (8) abdomen; and (9) musculoskeletal system. An assessment of the nervous system was conducted; any findings were captured under the appropriate body area. Each system was assessed as normal or abnormal.

Time frame:
Baseline and Week 52
Reported as:
Number · participants
Physical Examination Findings
participantsVortioxetine
Appearance at Baseline: Normal758
Appearance at Baseline: Abnormal76
Appearance at Week 52: Normal484
Appearance at Week 52: Abnormal40
Extremities at Baseline: Normal806
Extremities at Baseline: Abnormal28
Extremities at Week 52: Normal511
Extremities at Week 52: Abnormal13
Skin at Baseline: Normal730
Skin at Baseline: Abnormal104
Skin at Week 52: Normal465
Skin at Week 52: Abnormal59
Head-Neck at Baseline: Normal822
Head-Neck at Baseline: Abnormal12
Head-Neck at Week 52: Normal518
Head-Neck at Week 52: Abnormal6
Eyes-Ears-Nose-Throat at Baseline: Normal772
Eyes-Ears-Nose-Throat at Baseline: Abnormal62
Eyes-Ears-Nose-Throat at Week 52: Normal485
Eyes-Ears-Nose-Throat at Week 52: Abnormal39
Lungs-Chest at Baseline: Normal827
Lungs-Chest at Baseline: Abnormal7
Lungs-Chest at Week 52: Normal523
Lungs-Chest at Week 52: Abnormal1
Heart/Cardiovascular at Baseline: Normal816
Heart/Cardiovascular at Baseline: Abnormal18
Heart/Cardiovascular at Week 52: Normal512
Heart/Cardiovascular at Week 52: Abnormal12
Abdomen at Baseline: Normal818
Abdomen at Baseline: Abnormal12
Abdomen at Baseline: Not done4
Abdomen at Week 52: Normal515
Abdomen at Week 52: Abnormal8
Abdomen at Week 52: Not done1
Musculoskeletal at Baseline: Normal790
Musculoskeletal at Baseline: Abnormal44
Musculoskeletal at Week 52: Normal493
Musculoskeletal at Week 52: Abnormal31
PrimaryNumber of Participants With Potentially Clinically Significant Laboratory Evaluation Findings

Participants with at least one post-baseline potentially clinically significant (as defined in the table below) serum chemistry, hematology or urinalysis result. ULN = upper limit of normal; LLN = Lower limit of normal.

Time frame:
Weeks 4, 8, 12, 20, 28, 36, 44 and 52
Reported as:
Number · participants
Number of Participants With Potentially Clinically Significant Laboratory Evaluation Findings
participantsVortioxetine
Alanine aminotransferase (ALT) ≥ 3 X ULN3
Aspartate aminotransferase (AST) ≥ 3 X ULN6
Bilirubin ≥ 34.2 μmol/L1
Cholesterol ≥ 7.8 mmol/L49
Creatine kinase ≥ 2 X ULN80
Creatinine ≥ 175 μmol/L1
Glucose ≤ 2.8 mmol/L9
Glucose ≥ 13.9 mmol/L7
High density lipoprotein cholesterol < 0.9 mmol/L102
Low density lipoprotein cholesterol ≥ 5.0 mmol/L69
Potassium ≤ 3.0 mmol/L0
Potassium ≥ 5.5 mmol/L45
Sodium ≤ 125 mmol/L1
Sodium ≥ 155 mmol/L1
Triglycerides ≥ 3.40 mmol/L168
Urate ≤ 0.7 X LLN4
Urate ≥ 1.3 XULN12
Eosinophils ≥ 0.6 10^9/L24
Erythrocytes ≤ 0.9 X LLN9
Erythrocytes ≥ 1.1 X ULN1
Hematocrit ≤ 0.9 X LLN16
Hemoglobin ≤ 0.9 X LLN41
Leukocytes ≤ 2.8 X 10^9/L10
Leukocytes ≥ 16 X 10^9/L3
Lymphocytes ≤ 0.6 X 10^9/L5
Lymphocytes ≥ 7 X 10^9/L0
Neutrophils ≤ 1.4 X 10^9/L26
Neutrophils ≥ 15 X 10^9/L2
PrimaryNumber of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Findings

A standard 12-lead ECG was performed at the designated study visits. The central reader reviewed and recorded the intervals (PR, QRS, RR, QT, and corrected QT interval \[QTc\]), and interpreted the ECG using 1 of the following categories: within normal limits or abnormal. The number of participants with at least one post-baseline potentially clinically significant ECG finding is reported. bpm = beats per minute; QTcB = QT interval corrected using Bazett's formula; QTcF = QT interval corrected using Fridericia's formula.

Time frame:
Weeks 4, 12, 24, 36 and 52
Reported as:
Number · participants
Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Findings
participantsVortioxetine
Heart rate ≤50 bpm and change ≤-15bpm9
Heart rate ≥120 bpm and change ≥15 bpm0
RR interval <500 msec and change ≤-200 msec0
RR interval >1200 msec and change ≥200 msec13
PR interval <120 msec31
PR interval ≥250 msec2
QT interval <280 msec0
QT interval >500 msec2
QTcB <340 msec0
QTcB >500 msec3
QTcB Change <-60 msec6
QTcB Change >60 msec4
QTcF <340 msec0
QTcF >500 msec2
QTcF Change <-60 msec3
QTcF Change >60 msec2
PrimaryNumber of Participants With Adverse Events (AEs)

The intensity (severity) of each AE was defined as: * Mild: caused minimal discomfort and did not interfere in a significant manner with normal activities. * Moderate: sufficiently uncomfortable to produce some impairment of normal activities. * Severe: incapacitating, preventing the patient from participating in normal activities. The causal relationship between an AE and study drug was assessed by the investigator as Probable, Possible or Not Related; Related=AEs with causality of Possibly or Probably. A serious AE (SAE) was defined as any untoward medical occurrence that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, led to a congenital anomaly/birth defect, or was an important medical event that either jeopardized the patient, required intervention to prevent any of the SAEs defined above, a suicide attempt or an abortion.

Time frame:
From the first dose of open-label study drug until 4 weeks after the last dose (up to 56 weeks)
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs)
participantsVortioxetine
Any adverse event589
Related adverse event413
Not related adverse event176
Mild adverse event187
Moderate adverse event320
Severe adverse event82
Adverse event leading to early termination50
Serious adverse event29
Serious related adverse event5
Serious not related adverse event33
Serious adverse event leading to early termination11
Deaths0
PrimaryNumber of Participants With Potentially Clinically Significant Vital Sign Findings

Participants with at least one potentially clinically significant post-baseline vital sign finding. The definition of clinically significant is included in the table below for each parameter. SSBP = supine systolic blood pressure; SDBP = supine diastolic blood pressure.

Time frame:
Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 36, 44 and 52
Reported as:
Number · participants
Number of Participants With Potentially Clinically Significant Vital Sign Findings
participantsVortioxetine
SSBP ≤90 mmHg and decrease of ≥20 mmHg7
SSBP ≥180 mmHg and increase of ≥20 mmHg4
SDBP ≤50 mmHg and decrease of ≥15 mmHg1
SDBP ≥105 mmHg and increase of ≥15 mmHg8
Supine pulse rate ≤50 bpm and decrease of ≥15 bpm7
Supine pulse rate ≥120 bpm and increase of ≥15 bpm2
Weight Change of ≥7% weight155
SecondaryChange From Baseline in Hamilton Depression Scale-24 Item (HAM-D24) Total Score

The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74 where a higher score indicates a greater depressive state. Final Visit includes data from Week 52 or earlier for participants who didn't complete the 52 weeks.

Time frame:
Baseline and Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 36, 44 and 52.
Reported as:
Mean · scores on a scale
Change From Baseline in Hamilton Depression Scale-24 Item (HAM-D24) Total Score
scores on a scaleVortioxetine
Week 1 (n=805)-1.1 ± 5.27
Week 2 (n=822)-3.1 ± 6.10
Week 4 (n=805)-4.7 ± 7.07
Week 8 (n=752)-6.5 ± 7.43
Week 12 (n=715)-7.0 ± 8.27
Week 16 (n=671)-7.7 ± 8.45
Week 20 (n=639)-8.4 ± 8.51
Week 24 (n=613)-8.3 ± 8.92
Week 28 (n=599)-8.9 ± 8.91
Week 36 (n=568)-9.3 ± 9.05
Week 44 (n=540)-9.6 ± 9.32
Week 52 (n=522)-10.0 ± 8.86
Final Visit (n=829)-7.9 ± 9.66
SecondaryChange From Baseline in the Montgomery Åsberg Depression Rating Scale (MADRS) Total Score

The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). Decrease in the total score or on individual items indicates improvement. Final Visit includes data from Week 52 or earlier for participants who didn't complete the 52 weeks.

Time frame:
Baseline and Weeks 4, 24 and 52
Reported as:
Mean · scores on a scale
Change From Baseline in the Montgomery Åsberg Depression Rating Scale (MADRS) Total Score
scores on a scaleVortioxetine
Week 4 (n=818)-4.5 ± 7.38
Week 24 (n=642)-7.9 ± 9.24
Week 52 (n=526)-9.5 ± 8.90
Final Visit (n=818)-7.4 ± 9.81
SecondaryChange From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score

The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56, where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. Final Visit includes data from Week 52 or earlier for participants who didn't complete the 52 weeks.

Time frame:
Baseline and Weeks 4, 24 and 52
Reported as:
Mean · scores on a scale
Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score
scores on a scaleVortioxetine
Week 4 (n=818)-2.9 ± 5.12
Week 24 (n=642)-5.1 ± 6.44
Week 52 (n=527)-6.6 ± 6.38
Final Visit (n= 818)-5.2 ± 6.76
SecondaryChange From Baseline in the Clinical Global Impression of Severity of Illness Scale

The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. Final Visit includes data from Week 52 or earlier for participants who didn't complete the 52 weeks.

Time frame:
Baseline and Weeks 4, 24 and 52
Reported as:
Mean · scores on a scale
Change From Baseline in the Clinical Global Impression of Severity of Illness Scale
scores on a scaleVortioxetine
Week 4 (n=818)-0.53 ± 1.002
Week 24 (n=642)-0.98 ± 1.295
Week 52 (n= 527)-1.33 ± 1.266
Final Visit (n=818)-1.00 ± 1.338
SecondaryChange From Baseline to the Final Visit in 36-item Short-form Health Survey (SF-36)

The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The 8 health concepts are: 1. Limitation in physical activities because of health problems. 2. Limitations in usual role activities because of physical health problems. 3. Bodily pain. 4. Limitations in social activities because of physical or emotional problems. 5. General mental health (psychological distress and well-being). 6. Limitations in usual role activities because of emotional problems. 7. Vitality (energy and fatigue). 8. General health perception. Each scale ranges from 0 (best) - 100 (worst).

Time frame:
Baseline and Week 52
Reported as:
Mean · scores on a scale
Change From Baseline to the Final Visit in 36-item Short-form Health Survey (SF-36)
scores on a scaleVortioxetine
Physical functioning subscore (n=824)4.5 ± 15.88
Role-physical subscore (n=824)8.1 ± 25.51
Bodily pain subscore (n=824)4.9 ± 24.29
General health subscore (n=823)6.4 ± 18.38
Vitality subscore (n=824)10.1 ± 23.03
Social functioning subscore (n=824)10.9 ± 26.90
Role-emotional subscore (n=824)12.3 ± 28.24
Mental health subscore (n=824)10.7 ± 22.04
SecondaryChange From Baseline to the Final Visit in the Sheehan Disability Scale

The Sheehan Disability Scale (SDS) assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment.

Time frame:
Baseline and Week 52
Reported as:
Mean · scores on a scale
Change From Baseline to the Final Visit in the Sheehan Disability Scale
scores on a scaleVortioxetine
Change From Baseline to the Final Visit in the Sheehan Disability Scale-4.6 ± 8.01
SecondaryHealth Care Resource Utilization Assessed by the Health Economic Assessment Questionnaire

Healthcare resource utilization was assessed by the Health Economic Assessment (HEA) questionnaire, which monitors participants absenteeism from work, as well as resource use such as visits to a general practitioner, outpatient and inpatient services, hospitalization, medications, and other relevant services over the past 8 weeks.

Time frame:
Baseline and Week 52
Reported as:
Number · participants
Health Care Resource Utilization Assessed by the Health Economic Assessment Questionnaire
participantsVortioxetine
Baseline: Any resource use137
Baseline: Any hospitalization-related services4
Baseline: Hospitalization related to depression0
Baseline: Any sick leave53
Baseline: Sick leave related to depression42
Week 52: Any resource use138
Week 52:Any hospitalization-related services7
Final Visit: Hospitalization related to depression0
Week 52: Any sick leave41
Week 52: Sick leave related to depression25

Adverse events

Collected over From first dose of study until 30 days after the last dose.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vortioxetine—29/834 (3.5%)452/834 (54.2%)
Most frequent serious events
Showing 10 of 36
Most frequent serious events
EventVortioxetine
InfluenzaInfections and infestations2/834
Suicidal ideationPsychiatric disorders2/834
AnemiaBlood and lymphatic system disorders1/834
Atrial fibrillationCardiac disorders1/834
Coronary artery diseaseCardiac disorders1/834
Myocardial infarctionCardiac disorders1/834
Supraventricular tachycardiaCardiac disorders1/834
TachycardiaCardiac disorders1/834
Tachycardia paroxysmalCardiac disorders1/834
Umbilical hernia, obstructiveGastrointestinal disorders1/834
Most frequent other events
Showing 10 of 20
Most frequent other events
EventVortioxetine
NauseaGastrointestinal disorders127/834
HeadacheNervous system disorders102/834
NasopharyngitisInfections and infestations82/834
DiarrhoeaGastrointestinal disorders60/834
DizzinessNervous system disorders57/834
Upper respiratory tract infectionInfections and infestations53/834
Weight increasedInvestigations36/834
InfluenzaInfections and infestations33/834
SomnolenceNervous system disorders33/834
Back painMusculoskeletal and connective tissue disorders32/834

Baseline characteristics

Age Continuous
Age Continuous(Years)Vortioxetine
Mean45.5 ± 12.78
Age, Customized
Age, Customized(Participants)Vortioxetine
≤55 years636
>55 years200
Sex: Female, Male
Sex: Female, Male(Participants)Vortioxetine
Female526
Male310
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Vortioxetine
Caucasian (White, including Hispanic)693
Black86
Asian54
American Indian or Alaska Native2
Native Hawaiian/ Other Pacific Islander1
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Vortioxetine
Hispanic/Latino53
Non-Hispanic/Non-Latino782
Missing1
Region of Enrollment
Region of Enrollment(Participants)Vortioxetine
Australia4
Germany207
France11
Croatia11
Republic of Korea25
Lithuania10
Latvia20
Malaysia17
Netherlands7
Poland57
Russia40
Taiwan3
Ukraine37
United States387
Weight
Weight(kg)Vortioxetine
Mean81.16 ± 20.829
Height
Height(cm)Vortioxetine
Mean169.00 ± 9.777

5 further baseline measures are reported on the registry.

08

Study locations

92 sites
  • Beverly Hills, California, United States
  • Irvine, California, United States
  • Santa Ana, California, United States
  • Torrance, California, United States
  • Upland, California, United States
  • Bradenton, Florida, United States
  • Coral Springs, Florida, United States
  • Fort Walton Beach, Florida, United States
  • Gainesville, Florida, United States
  • Jacksonville, Florida, United States
  • Maitland, Florida, United States
  • Orlando, Florida, United States
  • South Miami, Florida, United States
  • West Palm Beach, Florida, United States
  • Atlanta, Georgia, United States
  • Smyrna, Georgia, United States
  • Chicago, Illinois, United States
  • Libertyville, Illinois, United States
  • Oak Brook, Illinois, United States
  • Prairie Village, Kansas, United States
  • Owensboro, Kentucky, United States
  • Baltimore, Maryland, United States
  • Pittsfield, Massachusetts, United States
  • Worcester, Massachusetts, United States
  • Flowood, Mississippi, United States
  • New York, New York, United States
  • Olean, New York, United States
  • Beachwood, Ohio, United States
  • Toledo, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Allenton, Pennsylvania, United States
  • Lancaster, Pennsylvania, United States
  • Memphis, Tennessee, United States
  • Austin, Texas, United States
  • San Antonio, Texas, United States
  • Salt Lake City, Utah, United States
  • Seattle, Washington, United States
  • Milwaukee, Wisconsin, United States
  • Elizabeth Vale, Australia
  • Richmond, Australia
  • Southport, Australia
  • Osijek, Croatia
  • Zagreb, Croatia
  • Bully les Mines, France
  • Marseille, France
  • Strasbourg, France
  • Berlin, Germany
  • Bochum, Germany
  • Chemnitz, Germany
  • Huettenberg, Germany
  • Leipzig, Germany
  • München, Germany
  • Nuernberg, Germany
  • Wiesbaden, Germany
  • Buchon, Korea, Republic of
  • Gyeonggi-do, Korea, Republic of
  • Incheon, Korea, Republic of
  • Seoul, Korea, Republic of
  • Liepaja, Latvia
  • Riga, Latvia
  • Sigulda, Latvia
  • Siauliai, Lithuania
  • Vilnius, Lithuania
  • Kuala Lumpur, Malaysia
  • SchHoogfliet, Netherlands
  • Wildervank, Netherlands
  • Zwijndrecht, Netherlands
  • Białystok, Poland
  • Leszno, Poland
  • Pruszków, Poland
  • Skórzewo, Poland
  • Toruń, Poland
  • Tuszyn, Poland
  • Moscow, Russian Federation
  • Nizhny Novgorod, Russian Federation
  • Novosibirsk, Russian Federation
  • Omsk, Russian Federation
  • St. Petersburg, Russian Federation
  • Stavropol, Russian Federation
  • Tomsk, Russian Federation
  • Belgrade, Serbia
  • Bryanston, South Africa
  • Durban, South Africa
  • Lyttelton, South Africa
  • NoordHeuwel, South Africa
  • Pretoria, South Africa
  • Kaohsiung, Taiwan
  • Dnepropetrovsk, Ukraine
  • Kiev, Ukraine
  • Lugansk, Ukraine
  • Simferopol, Ukraine
  • Glasgow, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of Jul 2010 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2013, 3 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2008
First posted
Jul 2, 2008
Start
Jun 2008
Primary completionActual
Jul 2010
CompletionActual
Aug 2010
Results first posted
Dec 13, 2013
Last update
Dec 13, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00707980
Lead sponsor
Takeda
Collaborators
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Jul 2, 2008
Start date
Jun 2008
Primary completion
Jul 2010
Completion
Aug 2010
Results posted
Dec 13, 2013
Last update
Dec 13, 2013

Study contacts

Medical Director, Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion